The phenotype of MM progenitors that generate tumors in immune-compromised mice is controversial, particularly their expression of CD138 [26, 27], the marker that discriminates early PCs (sensitive to lenalidomide) from PBs (poorly sensitive) in the current report. The gene discussed is SDC1; the disease is Miyoshi myopathy.